July 1, 2013

North America’s first Sysmex XN-9000 goes live at Mercy Medical Center for faster diabetes testing

Mercy Medical Center recently implemented advanced clinical laboratory diagnostics technology for conducting on-demand, Hemoglobin A1c (HbA1c) diabetes testing, as well as analysis of important red blood cell, white blood cell and platelet counts. The new system enables the hospital to provide faster, more accurate lab results for physicians and their patients, which can improve treatment decisions.

As North America’s first installation of its kind, the Sysmex Lavender Top Management® system, designed and manufactured by Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and Sysmex America, builds on Mercy’s Sysmex XN-9000™system and further optimizes lab workflow, staffing and space.

Mary Ann Burich-Boccia, administrative director of Mercy Laboratory Services, believes upgrading and standardizing the lab with the XN-9000 Lavender Top Management configuration means the hospital can continue to stay ahead of testing complexities and provide quality HbA1c testing and results on a 24/7 basis.

“This powerful new platform will greatly benefit patients in our community, many of whom suffer from diabetes, and it will contribute to positive patient outcomes,” she says. “Our previous platform was the original Lavender Top Management, and we were able to achieve all our expected productivity gains. The XN-9000 allows us to continue to improve even further.”

New System Incorporates Latest in Automation Technology
The XN-9000, a scalable, configurable automation system, integrates multiple XN modules, including the Sysmex RU-20™ concentrated reagent dilution unit; sample sorting and archiving provided by the PVT LabSystems® TS-500; WAM™ decision support software; and Bio-Rad’s VARIANT™ II TURBO Link for on-demand HbA1c testing.

With its new system, Mercy will also perform:
• NRBCs (fluorescent nucleated red blood cell count) with every CBC (complete blood count)
• IG (Immature granulocyte enumeration) with every differential
• RET-He (Reticulocyte hemoglobin) as a parameter in the reticulocyte profile
• IPF (Immature platelet fraction) to aid clinicians in the assessment of thrombocytopenia

XN-9000 Plays Critical Role in Determining Diabetes Control
The XN-9000 uses HPLC (high-performance liquid chromatography) technology – the gold standard for HbA1c testing – to perform HbA1c analysis, which measures the amount of glucose attached to the hemoglobin in the red blood cell and estimates blood glucose control during the previous three to four months.

According to the American Diabetes Association, diabetes affects more than 25 million children and adults in the United States, or 8.3 percent of the population. It can increase a person’s risk for developing serious complications, including heart disease and stroke, high blood pressure, blindness, kidney and nervous system diseases. Proper management of the chronic condition can delay or even prevent the onset of complications, allowing patients to live healthier, more productive lives.

Mercy Medical Center is a ministry of the Sisters of Charity Health System.

About Us

From its Cleveland headquarters, the Sisters of Charity Health System provides oversight, leadership and strategic direction to more than 20 organizations responding to community needs in Canton and Cleveland, Ohio, and South Carolina.

Follow us on Twitter

Archives